Terminal colon cancer patient saved by breakthrough treatment
Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience.
Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience.
Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience. Generate Key Takeaways
Two years ago, Emma Dimery was told her stage 4 colon cancer was incurable. Today, she is healthy and cancer-free — and she says a last-resort clinical trial saved her life.
Dimery, who lives in Minnesota, was just 23 when she was diagnosed with colon cancer, which has been rising sharply among teens and young adults in recent years.
After experiencing abdominal pain and having abnormal blood work, Dimery underwent a colonoscopy, which revealed a "softball-sized" tumor and another "golf ball-sized" one, she told Fox News Digital.
Alternative Cancer Treatment Could Replace Chemo And Surgery, Study Suggests
Despite multiple surgeries, chemotherapy, radiation and some combination therapies, Dimery's treatment-resistant cancer spread throughout her body over the years, leading to what she described as a "low point."
Emma Dimery is shown during the first phase of the clinical trial.
"I was basically treading water, doing immunotherapy every other week for probably four years or so," she told Fox News Digital during an on-camera interview, adding that she was "out of options." (See the video at the top of the article.)
Read On The Fox News App
"I had been waiting for a clinical trial," recalled Dimery, now 35. "I had exhausted every other standard of treatment, and even some not-so-standard ones."
When Dimery heard about a new trial at the University of Minnesota, she said it "wasn't a tough decision."
"I was on board pretty much from day one," she said.
The trial, led by Dr. Emil Lou, tested an experimental genetic therapy that the researcher described as the "next frontier of immunotherapy."
Woman Says Dog Detected Her Breast Cancer Before Doctors Did: 'He's Known This Whole Time'
While most immunotherapies have targets that are on the outside of cells, this one targeted the insides of cells.
"Some of the targets inside the cell are preventing the immune system from activating against the cancer," Lou, a medical oncologist and scientist who had previously treated Dimery, told Fox News Digital in an on-camera interview. "It's kind of like a shield that protects the cancer cell from the body's immune system."
In 2023, Emma Dimery is pictured in the hospital with her care exam during the clinical trial with her care team.
In the trial, cancer cells were retrieved from the participants, then were altered in a lab using CRISPR-Cas9 gene editing technology, which Lou described as "genetic scissors." The process programmed the cells to have a more effective anti-tumor response.
The altered cells were then reintroduced into the patients' bodies via infusion.
"They trained the cells to be able to fight my cancer specifically when they were reintroduced into my body," Dimery noted.
It was a long process that was grueling at times, she shared, with some challenging side effects.
"You just get through it and try to focus on the good," Dimery said. "And I had a lot of good around me. I had really amazing support team."
A total of 12 patients participated in the study — but Dimery had by far the best results.
The vast majority of advanced colorectal cancers are not considered to be curable, Lou confirmed to Fox News Digital.
"The chemotherapies or whatever other treatments we have available, while there are a number of them, are palliative — meaning they don't have the capability to induce a cure in patients with metastatic stage 4 colorectal cancers," he said.
"Emma was in that category until she came onto our trial."
Emma Dimery and her husband Andrew celebrate after buying a home right after she was released from the hospital after the trial in 2023.
Lou described Dimery's response to the experimental immunotherapy as "remarkable." After just one infusion of the engineered cells, she was pronounced cancer-free — an outcome that is "almost unheard-of" with advanced colorectal cancer.
"We term this in oncology as a 'clinical complete response,' which is something that you see in 10% or less of all patients," Lou said. "And it's less than 10% for stage 4 colorectal cancers."
Woman Says Chatgpt Saved Her Life By Helping Detect Cancer, Which Doctors Missed
"What we saw in Emma was a magnificent and unprecedented level of response, going from a metastatic stage for an otherwise incurable cancer … where now we don't see any cancer."
Two years after the trial, Dimery said she's doing "really well."
Emma Dimery is pictured with her sister, Anne Johnson, during a 2017 hospital stay.
"The trial worked almost immediately — and I've had no evidence of disease since," she told Fox News Digital.
While she's hesitant to use "the C-word," or "cure," she said the trial has changed the way she thinks of cancer.
"Until now, the best I could hope for was remission to the point of no evidence of disease … and had to accept that it could rear its head again at any point, even if they can't detect it on a scan," Dimery said.
"All of my scans have just been coming back better and better."
"You just get through it and try to focus on the good," Dimery said in an on-camera interview with Fox News Digital. "And I had a lot of good around me. I had really amazing support team."
Dimery's story was unveiled last week at the American Association for Cancer Research (AACR) Annual Meeting in Chicago.
"Emma is exceptional in many ways, but what we learned from her case, we hope to replicate and decipher how we can achieve this on a more consistent basis across the board for more patients like her," Lou added.
Studies have shown that in 2023, one in 10 colorectal cancer diagnoses were considered early-onset, or affecting patients under 50 years of age.
The American College of Surgeons predicts that early-onset cases will double by 2030.
Emma Dimery is pictured in 2013, at just 23 years, after receiving her initial cancer diagnosis.
"Colorectal cancer remains one of the few cancers for which we have validated screening tools," Lou noted.
Those include blood-based tests, stool-based tests and colonoscopies.
In 2018, the American Cancer Society changed its colorectal screening recommendation from age 50 to age 45. Other medical organizations followed suit in ensuing years.
Even so, Lou said he is seeing patients diagnosed well ahead of the age 45 benchmark.
"I'm seeing something in the last five or six years that I really did not see earlier in my career — teenagers, people in their 20s, 30s and 40s," he shared.
"Just last week, I saw someone in their early 40s with widely metastatic stage 4 colorectal cancer."
Click Here To Sign Up For Our Health Newsletter
What's "striking and alarming," Lou said, is that about half of the cases of colorectal cancer are diagnosed at stage 4.
"A lot of times, they don't even have symptoms, or they have symptoms that were construed as something else."
The more people who are aware, the better. I think it's really important to not panic, but to stay informed and connected to the community," said Emma Dimery, pictured in 2021 during an Immunotherapy treatment.
Dimery said she is encouraged by early-onset colon cancer coming to the "forefront of public consciousness."
The more people who are aware, the better. I think it's really important to not panic, but to stay informed and connected to the community."
For more Health articles, visit www.foxnews.com/health
Genetic testing is also important to gauge the availability of clinical trials, she noted.
"That can tell you a lot about your individual type of cancer," Dimery said. "Luckily for me, I had just the right kind of cancer for this treatment."
Original article source: Terminal colon cancer patient saved by breakthrough treatment

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Seek Labs Maps Measles Virus with BioSeeker™, Opening the Door to First-Ever Programmable Antiviral Therapeutic Amid Global Outbreaks
SALT LAKE CITY, June 23, 2025--(BUSINESS WIRE)--Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced the successful mapping of conserved therapeutic targets within the measles virus (MeV) genome using BioSeeker™, the company's proprietary AI-powered discovery engine. Amid rising measles outbreaks worldwide, this breakthrough marks a foundational step toward developing the world's first programmable antiviral therapeutic for measles, leveraging Seek Labs' CRISPR-based Programmable Target Ablation Platform (PTAP™). BioSeeker scanned thousands of publicly available measles virus isolates, identifying a multiplexed set of high-impact, PTAP-compatible genomic targets (stable, conserved regions most critical to viral replication). These sites form a blueprint for CRISPR-based "seek-and-destroy" therapeutics capable of irreversibly disabling the virus with speed, specificity, and resilience against resistance. "This is exactly why we built BioSeeker; to deliver smarter, faster weapons against viral diseases that still lack effective treatments," said Jared Bauer, CEO of Seek Labs. "There are no targeted therapeutics for measles once infection occurs. With BioSeeker, we can now design a precision treatment that shuts down the virus at its source, unlocking a powerful new paradigm for global health." A Game-Changing Response to the Measles Crisis Measles is one of the most contagious viruses in the world, spreading through airborne droplets and capable of causing severe complications, which include pneumonia, encephalitis, and death. Recent surges, such as the nearly 200,000 cases globally in early 2025, have placed renewed strain on public health systems and highlight the urgent need for scalable antiviral interventions. The urgency of this breakthrough is underscored by Utah's recent confirmation of its first measles case amid an ongoing national outbreak. As Seek Labs is headquartered in Salt Lake City, this development brings the crisis closer to home and emphasizes a critical need for accelerated antiviral solutions, especially in areas where vaccination rates remain low or immunity wanes. While Seek Labs is not advancing this candidate in-house, the company will make its complete BioSeeker-generated measles guide set available to qualified partners and is actively seeking collaborators to accelerate preclinical development. "We've done the foundational work and now we're inviting bold partners to help turn it into a breakthrough," said Kim Wirthlin, Chief Strategy Officer. "This is a first-of-its-kind opportunity to co-develop a targeted antiviral for measles and reshape how the world responds to this disease." Part of a Global Disease Atlas to Outpace Emerging Threats This milestone is part of Seek Labs' broader initiative to build a Global Disease Atlas, a real-time, AI-powered genomic map of the world's most dangerous pathogens. The Atlas is on track to map over 95% of high-burden viral threats across both human and animal health, guiding the development of pan-pathogen, programmable therapeutics and diagnostics designed to adapt faster than viral evolution. Powered by BioSeeker, the Atlas enables faster decision-making, smarter intervention points, and scalable innovation across public health, biodefense, and pandemic preparedness. Seek Labs is actively partnering with biopharma, government, and global health organizations to move these discoveries into the clinic. Organizations interested in licensing, partnerships, or deploying these innovations for public health impact are encouraged to contact Seek Labs directly. About Seek Labs At Seek Labs, we don't wait for change—we build it. We're seeking the breakthroughs the world can't wait for by developing programmable "seek and destroy" therapeutics and point-of-care molecular diagnostics that close the gap between outbreak and intervention. Powered by our AI discovery engine, BioSeeker™, these platforms form a full-stack development engine—from target discovery to real-world deployment—designed to accelerate innovation and impact across global health. Headquartered in Salt Lake City, Seek Labs is a proud member of BioHive, Utah's collaborative life sciences ecosystem. Together with our partners, we're building faster, smarter solutions for the world's most urgent health challenges. Forward-Looking Statements and Regulatory Disclaimer This press release includes forward-looking statements about Seek Labs' technologies, development plans, and partnership opportunities. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ. The technologies described are investigational and have not been reviewed or approved by the FDA or any other regulatory authority for clinical or commercial use. View source version on Contacts Bridget Baldwin, Director of Communications, communications@ Sign in to access your portfolio


Business Wire
an hour ago
- Business Wire
Seek Labs Maps Measles Virus with BioSeeker™, Opening the Door to First-Ever Programmable Antiviral Therapeutic Amid Global Outbreaks
SALT LAKE CITY--(BUSINESS WIRE)--Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced the successful mapping of conserved therapeutic targets within the measles virus (MeV) genome using BioSeeker™, the company's proprietary AI-powered discovery engine. Amid rising measles outbreaks worldwide, this breakthrough marks a foundational step toward developing the world's first programmable antiviral therapeutic for measles, leveraging Seek Labs' CRISPR-based Programmable Target Ablation Platform (PTAP™). Amid rising measles outbreaks worldwide, this breakthrough marks a foundational step toward developing the world's first programmable antiviral therapeutic for measles, leveraging Seek Labs' CRISPR-based Programmable Target Ablation Platform (PTAP™). BioSeeker scanned thousands of publicly available measles virus isolates, identifying a multiplexed set of high-impact, PTAP-compatible genomic targets (stable, conserved regions most critical to viral replication). These sites form a blueprint for CRISPR-based 'seek-and-destroy' therapeutics capable of irreversibly disabling the virus with speed, specificity, and resilience against resistance. 'This is exactly why we built BioSeeker; to deliver smarter, faster weapons against viral diseases that still lack effective treatments,' said Jared Bauer, CEO of Seek Labs. 'There are no targeted therapeutics for measles once infection occurs. With BioSeeker, we can now design a precision treatment that shuts down the virus at its source, unlocking a powerful new paradigm for global health.' A Game-Changing Response to the Measles Crisis Measles is one of the most contagious viruses in the world, spreading through airborne droplets and capable of causing severe complications, which include pneumonia, encephalitis, and death. Recent surges, such as the nearly 200,000 cases globally in early 2025, have placed renewed strain on public health systems and highlight the urgent need for scalable antiviral interventions. The urgency of this breakthrough is underscored by Utah's recent confirmation of its first measles case amid an ongoing national outbreak. As Seek Labs is headquartered in Salt Lake City, this development brings the crisis closer to home and emphasizes a critical need for accelerated antiviral solutions, especially in areas where vaccination rates remain low or immunity wanes. While Seek Labs is not advancing this candidate in-house, the company will make its complete BioSeeker-generated measles guide set available to qualified partners and is actively seeking collaborators to accelerate preclinical development. 'We've done the foundational work and now we're inviting bold partners to help turn it into a breakthrough,' said Kim Wirthlin, Chief Strategy Officer. 'This is a first-of-its-kind opportunity to co-develop a targeted antiviral for measles and reshape how the world responds to this disease.' Part of a Global Disease Atlas to Outpace Emerging Threats This milestone is part of Seek Labs' broader initiative to build a Global Disease Atlas, a real-time, AI-powered genomic map of the world's most dangerous pathogens. The Atlas is on track to map over 95% of high-burden viral threats across both human and animal health, guiding the development of pan-pathogen, programmable therapeutics and diagnostics designed to adapt faster than viral evolution. Powered by BioSeeker, the Atlas enables faster decision-making, smarter intervention points, and scalable innovation across public health, biodefense, and pandemic preparedness. Seek Labs is actively partnering with biopharma, government, and global health organizations to move these discoveries into the clinic. Organizations interested in licensing, partnerships, or deploying these innovations for public health impact are encouraged to contact Seek Labs directly. About Seek Labs At Seek Labs, we don't wait for change—we build it. We're seeking the breakthroughs the world can't wait for by developing programmable 'seek and destroy' therapeutics and point-of-care molecular diagnostics that close the gap between outbreak and intervention. Powered by our AI discovery engine, BioSeeker™, these platforms form a full-stack development engine—from target discovery to real-world deployment—designed to accelerate innovation and impact across global health. Headquartered in Salt Lake City, Seek Labs is a proud member of BioHive, Utah's collaborative life sciences ecosystem. Together with our partners, we're building faster, smarter solutions for the world's most urgent health challenges. Forward-Looking Statements and Regulatory Disclaimer This press release includes forward-looking statements about Seek Labs' technologies, development plans, and partnership opportunities. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ. The technologies described are investigational and have not been reviewed or approved by the FDA or any other regulatory authority for clinical or commercial use.
Yahoo
3 hours ago
- Yahoo
3 Things Parents Know About Dealing with Mosquitoes and Bug Bites
This article may contain affiliate links that Yahoo and/or the publisher may receive a commission from if you buy a product or service through those links. There are so many things to love about summertime — the long days, relaxed schedules, and trips to the pool and the beach. But there are a few things about summer I would change if I could — my perpetual sweat mustache, the way storm clouds seem to hover whenever I fire up the grill, and top of the list, the onslaught of mosquitos. Mosquitos see me (and my younger child) as their own personal buffet, and they seem to be unable to get their fill, so I'm always looking for ways to keep the bugs at bay so that I'm not riddled with itchy mosquito bites. I'm not alone in my struggle against these little flying pests. Faith Durand, Apartment Therapy's SVP of content and EIC of Cubby, shares my animosity toward the backyard bugs. Lucky for me, she's done a ton of research to find the best products on the market. Faith knows that combating mosquitos requires a multipronged attack that includes solutions for repelling mosquitos and preventing bites. In this article for Cubby, she highlights the best products for avoiding bites, more intimate outdoor scenarios, and hosting bigger outdoor I Tried (and Failed) to Keep Mosquitoes Away for Years — Then I Found 3 Products That Really Work Where I live, in swampy Richmond, Virginia, mosquitos are a fact of life all summer long, so I've tried dozens of repellents to try to keep myself and my family bite-free. But since we have sensitive skin, that rules out a ton of the options on the market. Add a dislike of overpowering smells and greasy residues, and we're left with even fewer options. It can be overwhelming to find a bug spray that meets our needs and is also safe for kids. So, I was delighted to read Trisha Sprouse's review of an effective Deet-free bug spray that she and her family can tolerate. In this article for Cubby, she shares the chic-looking repellent is available as a spray or in travel-friendly wipes, and the mild, citrusy scent is reminiscent of an Orange This DEET-Free Bug Spray Is the Only One My Kids Don't Hate Inevitably, even with the best prevention in place, you'll probably end up with a mosquito bite or two (or, if you're like me, a dozen) before the end of the summer, and we all know how itchy and annoying those bites can be, especially for little kids. Cubby Executive Editor Cambria Bold discovered an ingenious trick for soothing pesky bug bites with an unexpected product that you might have on hand, especially if you have a baby in the The Unusual Yet Practically Magical Product I Use to Stop Itchy Mosquito Bites Home: Where Your Story Starts How a Cheerful DIY 'Drop Zone' Made This Whole Space Work Smarter 3 DIY Paint Projects with Pro Results Sign up for Apartment Therapy's Daily email newsletter to receive our favorite posts, tours, products, and shopping guides in your inbox.